Glutamine News and Research

RSS

Glutamine is an amino acid used in nutrition therapy. It is also being studied for the treatment of diarrhea caused by radiation therapy to the pelvis.

Promising treatment for Huntington's disease soon to be tested clinically

At the Institut Curie, CNRS and Inserm researchers have shown that cysteamine, which is already used to treat a rare disease called cystinosis, prevents the death of neurons in Huntington's disease. Like Alzheimer's and Parkinson's, Huntington's disease, is characterized by the abnormal death of neurons.

19 Apr 2006

Possible molecular origin of at least nine human diseases of nervous system degeneration

These neurodegenerative diseases, including Huntington's disease, share an abnormal deposit of proteins inside nerve cells. This deposition of protein results from a kind of genetic stutter within the cell's nucleus asking for multiple copies of the amino acid glutamine, a building block of protein structure.

26 Sep 2005

Ataxin-1 affects the development of the nervous system

In some neurological diseases, too much of what is usually a good thing can be bad, said researchers at Baylor College of Medicine in a report in this week's issue of the journal Cell.

28 Aug 2005

Primordial soup where life began on earth was hot and not cold

A new theory that explains why the language of our genes is more complex than it needs to be also suggests that the primordial soup where life began on earth was hot and not cold, as many scientists believe.

2 Aug 2005

Psychiatric illness drugs may protect the brain cells that die in people with Huntington's disease

Researchers at UT Southwestern Medical Center have discovered that drugs commonly used to treat psychiatric illnesses and blood disorders in humans may protect the brain cells that die in people with Huntington's disease, possibly delaying the onset and slowing the progression of the disease.

31 Jan 2005

MGI PHARMA acquires Aesgen for $32 million

MGI PHARMA today announced that they have signed a definitive merger agreement under which MGI PHARMA will acquire all outstanding equity of Aesgen for $32 million in cash.

1 Sep 2004

$1.6 million ecological stoichiometry grant to study how certain nutrients affect the development of disease in humans and animals

Two University of Kansas and four Arizona State University researchers have received an almost $1.6 million grant from the National Science Foundation to study how certain nutrients affect the development of disease in humans and animals.

29 Jun 2004

Scientists closer to a potential vaccine or treatment for botulism

By deciphering the near atomic-level structure of the catalytic domain of botulinum toxin type E — one of seven neurotoxins that cause botulism, a disease that paralyzes victims by blocking nerve cells’ ability to communicate — scientists at the U.S. Department of Energy’s Brookhaven National Laboratory are one step closer to a potential vaccine or treatment.

10 May 2004

Design of artificial prion may aid fight against mad cow disease

The culprit behind mad cow disease, a.k.a. bovine spongiform encephalopathy, is the most infamous mammalian form of prions. Prions are misfolded proteins that are capable of growing, replicating, and being passed on to daughter cells, that is, they are by themselves heritable. Beyond their disease manifestation, prions also occur naturally in some organisms (such as yeast) and may play important roles in their growth and development. Now, Osherovich and colleagues have identified the amino acid sequences that allow prions to aggregate and replicate, and thereby pass through generations of cells - and prove this by designing an artificial yeast prion that does not exist in nature.

23 Mar 2004